BACKGROUND AND OBJECTIVE: To examine whether prophylactic use of haloperidol in addition to dexamethasone decreased the incidence of postoperative nausea and vomiting in high-risk patients undergoing ambulatory surgery. METHODS:One hundred and sixty nonsmoking women aged between 18 and 50 years receiving a standardized anaesthesia, which included dexamethasone 8 mg at the beginning of cosmetic or ENT surgery, were enrolled. They were randomized to receive either 1.5 mg of haloperidol (dexamethasone-haloperidol group) or placebo (dexamethasone-placebo group) 30 min before the end of surgery. The incidence of postoperative nausea and vomiting was assessed by a blinded investigator at 30 min, 2, 6, and 24 h in the postoperative period. Analgesic requirements, eye opening time, and sedation were also assessed. RESULTS: We found no differences in nausea or vomiting at 30 min and 2 h postoperatively; we found no difference in the incidence of nausea between dexamethasone-haloperidol and dexamethasone-placebo groups at 6 h [relative risk (RR) 0.82, 95% confidence interval (CI) 0.56-1.25] and 24 h (RR 0.79, 95% CI 0.56-1.1), but the cumulative incidence of vomiting in the dexamethasone-haloperidol group was significantly lower at 6 h (RR 0.57, 95% CI 0.39-1.05) and 24 h (RR 0.54, 95% CI 0.31-0.86). We found no differences in eye opening time and Ramsay score higher than 2 at 30 min and 2 h after surgery. CONCLUSION: To combine 1.5 mg of haloperidol and 8 mg of dexamethasone reduces the cumulative incidence of postoperative vomiting at 6 and 24 h postoperatively in day patients at high risk of postoperative nausea and vomiting.
RCT Entities:
BACKGROUND AND OBJECTIVE: To examine whether prophylactic use of haloperidol in addition to dexamethasone decreased the incidence of postoperative nausea and vomiting in high-risk patients undergoing ambulatory surgery. METHODS: One hundred and sixty nonsmoking women aged between 18 and 50 years receiving a standardized anaesthesia, which included dexamethasone 8 mg at the beginning of cosmetic or ENT surgery, were enrolled. They were randomized to receive either 1.5 mg of haloperidol (dexamethasone-haloperidol group) or placebo (dexamethasone-placebo group) 30 min before the end of surgery. The incidence of postoperative nausea and vomiting was assessed by a blinded investigator at 30 min, 2, 6, and 24 h in the postoperative period. Analgesic requirements, eye opening time, and sedation were also assessed. RESULTS: We found no differences in nausea or vomiting at 30 min and 2 h postoperatively; we found no difference in the incidence of nausea between dexamethasone-haloperidol and dexamethasone-placebo groups at 6 h [relative risk (RR) 0.82, 95% confidence interval (CI) 0.56-1.25] and 24 h (RR 0.79, 95% CI 0.56-1.1), but the cumulative incidence of vomiting in the dexamethasone-haloperidol group was significantly lower at 6 h (RR 0.57, 95% CI 0.39-1.05) and 24 h (RR 0.54, 95% CI 0.31-0.86). We found no differences in eye opening time and Ramsay score higher than 2 at 30 min and 2 h after surgery. CONCLUSION: To combine 1.5 mg of haloperidol and 8 mg of dexamethasone reduces the cumulative incidence of postoperative vomiting at 6 and 24 h postoperatively in day patients at high risk of postoperative nausea and vomiting.
Authors: Stephanie Weibel; Gerta Rücker; Leopold Hj Eberhart; Nathan L Pace; Hannah M Hartl; Olivia L Jordan; Debora Mayer; Manuel Riemer; Maximilian S Schaefer; Diana Raj; Insa Backhaus; Antonia Helf; Tobias Schlesinger; Peter Kienbaum; Peter Kranke Journal: Cochrane Database Syst Rev Date: 2020-10-19
Authors: Florian Brettner; Silke Janitza; Kathrin Prüll; Ernst Weninger; Ulrich Mansmann; Helmut Küchenhoff; Alexander Jovanovic; Bernhard Pollwein; Daniel Chappell; Bernhard Zwissler; Vera von Dossow Journal: PLoS One Date: 2016-01-11 Impact factor: 3.240
Authors: Jessica T Wegener; Tim Kraal; Markus F Stevens; Markus W Hollmann; Gino M M J Kerkhoffs; Daniël Haverkamp Journal: EFORT Open Rev Date: 2017-03-13